Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
01/06/202407:01Alliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:TGRTirupati Graphite Plc
01/06/202407:00Business WireMassive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
01/06/202407:00GlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
01/06/202407:00GlobeNewswire Inc.CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
01/06/202407:00Business WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)NYSE:PFEPfizer Inc
01/06/202407:00Business WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
01/06/202407:00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
01/06/202407:00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
01/06/202407:00Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:PFEPfizer Inc
01/06/202407:00Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
01/06/202407:00Business WireAccutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
01/06/202407:00GlobeNewswire Inc.OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
01/06/202407:00GlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
01/06/202407:00GlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
01/06/202407:00PR Newswire (US)Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual MeetingNYSE:LLYEli Lilly and Co
01/06/202407:00PR Newswire (US)BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
01/06/202407:00PR Newswire (Canada)L'AMC souligne le Mois national de l'histoire autochtone
01/06/202407:00PR Newswire (US)WLR Automotive Group Celebrates Employee Philanthropy with Generous Donations
01/06/202407:00PR Newswire (US)Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
01/06/202407:00PR Newswire (Canada)CMA reflects on National Indigenous History Month
01/06/202407:00PR Newswire (US)New Self-Help Book Empowers LGTBQ+ People, Parents, & Allies
01/06/202407:00PR Newswire (US)Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
01/06/202407:00PR Newswire (US)James Avery Artisan Jewelry Opens New Store at Westover Marketplace
01/06/202407:00PR Newswire (US)TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
01/06/202406:30CointelegraphUniswap Foundation postpones vote on incentivesCOIN:UNIUSDUniswap
01/06/202406:24PR Newswire (Canada)Le loyer étudiant moyen a augmenté de 20% en trois ans à Québec
01/06/202406:10PR Newswire (US)Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
01/06/202406:01GlobeNewswire Inc.Il documentario Life at the Yellow River Delta vince ai Telly Awards
01/06/202406:00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
01/06/202406:00PR Newswire (Canada)/R A P P E L -- Avis aux médias - Itinéraire du premier ministre pour le samedi 1 juin 2024/

Su Consulta Reciente